How does an insulin pump work, and how is it different from daily injections?

Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.

1. 1

   Insulin pump (Wikipedia)

   WikipediaPublished Sep 30, 2026Checked Oct 17, 2026

   “An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy (CSII = Continuous Subcutaneous Insulin Infusion). The device configuration may vary depending on design. A traditional pump includes: the pump (including controls, processing module, and batteries) a disposable reservoir for insulin (inside the pump) a disposable infusion set, including a cannula for subcutaneous insertion (under the skin) and a tubing system to connect the insulin reservoir to the cannula. Other configurations are possible. More recent models may include disposable or semi-disposable designs for the pumping mechanism and may eliminate tubing from the infusion set. An insulin pump is an alternative to multiple daily injections of insulin by insulin syringes or an insulin pen and allows for flexible insulin therapy when used in conjunction with blood glucose monitoring and carbohydrate counting.”

2. 2

   Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections for Glycemic Control in Pediatric Patients With Type 1 Diabetes Mellitus: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

   AACE endocrinology and diabetes (Calderon et al.)Published Dec 23, 2025Checked Oct 17, 2026

   “A systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Outcomes included HbA1c levels, total daily dose, diabetic ketoacidosis, hypoglycemia events, body mass index change, and adverse events. Statistical analysis was performed using R version 3.4.3.ResultsEighteen randomized controlled trials (1229 participants) were analyzed. CSII compared to MDI significantly reduced HbA1c (MD = -0.37%; 95% CI: -0.62 to -0.12; P P P P = 0.14), severe hypoglycemia (RR = 1.09; P = 0.73), or diabetic ketoacidosis (RR = 1.40; P = 0.43). Trial sequential analysis for HbA1c reduction indicated conclusive evidence, while for insulin requirements, it remains inconclusive due to insufficient sample size.ConclusionOur meta-analysis confirms CSII achieves superior HbA1c reduction versus MDI in pediatric type 1 diabetes, as supported by trial sequential analysis. However, evidence for insulin requirements remains inconclusive, highlighting the need for larger trials and personalized treatment considering patient preferences and accessibility.”

3. 3

   Comparative Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections on Glycemic Control in Pediatric Type 1 Diabetes: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.

   Journal of clinical medicine research (Fardan et al.)Published Aug 26, 2026Checked Oct 17, 2026

   “Trial sequential analysis (TSA) was employed to assess the sufficiency of evidence. Certainty of evidence was graded using the Grades of Recommendations Assessment, Development, and Evaluation (GRADE) approach.ResultsFourteen RCTs involving 659 participants were included. CSII was associated with a modest reduction in HbA1c compared to MDI (MD -0.36%; 95% confidence interval (CI), -0.80 to 0.08), although this did not reach statistical significance in the primary analysis (P = 0.098). However, sensitivity analysis excluding one large pragmatic trial revealed a significant benefit for CSII (MD -0.27%, P ConclusionsCSII may offer a modest glycemic advantage over MDI in pediatric T1DM without increasing safety risks; however, current randomized evidence is insufficient to universally recommend one modality over the other. Treatment choice should be personalized. Although the proportion of patients using automated insulin delivery (AID) is rising rapidly, CSII retains practical and cost advantages; future research should focus on modern AID systems.”

4. 4

   Recurrent diabetic ketoacidosis burden and precipitant patterns in established type 1 diabetes using continuous subcutaneous insulin infusion versus multiple daily injections: an 11-year retrospective single-center study.

   BMC endocrine disorders (Liu & Pan)Published Jul 10, 2026Checked Oct 17, 2026

   “In index admissions, hospital stay was shorter in CSII than in MDI (7.0 [5.0, 9.0] vs. 9.0 [7.0, 11.0] days; P = 0.006). Among adults, CSII was independently associated with lower odds of severe DKA (adjusted odds ratio 0.30, 95% confidence interval 0.11-0.77; P = 0.012). Recorded precipitating factors were summarized descriptively. Among recurrent CSII admissions, device/infusion-related failure was recorded in 7/30 admissions (23.3%); among recurrent MDI admissions, infection/intercurrent illness and insulin omission/insufficiency were recorded in 10/22 (45.5%) and 6/22 (27.3%) admissions, respectively.ConclusionsAmong patients with established type 1 diabetes who had experienced at least one DKA hospitalization, recurrent DKA was common. Recurrence was more frequent among patients classified as CSII users in the primary analysis, although the strength and statistical significance of this association varied across sensitivity analyses. Recorded precipitating factors suggested treatment-specific clinical contexts and should be interpreted descriptively.Clinical trial numberNot applicable.”

5. 5

   From algorithm to alarm: a narrative review on insulin delivery innovation.

   Annals of medicine and surgery (2012) (Saleem et al.)Published Jul 17, 2026Checked Oct 17, 2026

   “These systems autonomously regulate blood glucose levels, reducing the need for user intervention. Closed-loop devices outperform sensor-augmented pump (SAP) treatment in reducing hypoglycemia, extending the time-in-range, and lowering self-management responsibilities. In order to provide real-time control, closed-loop systems dynamically modify insulin delivery in response to glucose variations by using algorithms powered by artificial intelligence. Because SAP therapy depends more on user input and may not be as successful in providing consistent glycemic control, this capability helps overcome its drawbacks. Further improving overall safety and efficacy, the closed-loop technique decreases blood glucose variability.ConclusionThe two primary developments in diabetes care are sensor-augmented and closed-loop insulin devices, which offer better glucose control and lower hypoglycemia rates compared to traditional therapies. Closed-loop insulin delivery systems seem to be a more clinically successful option for controlling diabetes mellitus than SAP therapy.”

6. 6

   Driving-Related Glucose Monitoring Practices Among Insulin-Treated Adults With Type 2 Diabetes.

   Journal of diabetes science and technology (Barnard-Kelly et al.)Published May 30, 2026Checked Oct 17, 2026

   “Insulin regimens included basal-only therapy (54%, n = 257), multiple daily injections (39%, n = 197), and continuous subcutaneous insulin infusion (9%, n = 46). Severe hypoglycemic event(s) in the preceding 12 months were reported by 34%, and 54% had evidence of impaired awareness of hypoglycemia (Clarke score >4). Furthermore, 37% (n = 185) limited their driving due to insulin-related concerns, and 72% (n = 359) worried particularly about hypoglycemia. Only 34% (n = 168) reported checking glucose levels before driving >75% of the time. If feeling hypo before driving, 59% (n = 295) would take a snack but drive immediately. If feeling hypoglycemic while driving, 10% (n = 48) would attempt to 'get to their destination fast'. Only 27% (n = 138) carried fast-acting carbohydrates, and 42% (n = 210) felt safe to drive 'as soon as I feel better' while 32% (n = 163) would 'wait 45 minutes and recheck their glucose levels'.ConclusionsPotentially unsafe driving behaviors are common among adults with insulin-treated T2D. There appears to be a need to improve the understanding of safe driving guidance.”